374 related articles for article (PubMed ID: 29321523)
1. Integrative genomic and transcriptomic analysis of leiomyosarcoma.
Chudasama P; Mughal SS; Sanders MA; Hübschmann D; Chung I; Deeg KI; Wong SH; Rabe S; Hlevnjak M; Zapatka M; Ernst A; Kleinheinz K; Schlesner M; Sieverling L; Klink B; Schröck E; Hoogenboezem RM; Kasper B; Heilig CE; Egerer G; Wolf S; von Kalle C; Eils R; Stenzinger A; Weichert W; Glimm H; Gröschel S; Kopp HG; Omlor G; Lehner B; Bauer S; Schimmack S; Ulrich A; Mechtersheimer G; Rippe K; Brors B; Hutter B; Renner M; Hohenberger P; Scholl C; Fröhling S
Nat Commun; 2018 Jan; 9(1):144. PubMed ID: 29321523
[TBL] [Abstract][Full Text] [Related]
2. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
[TBL] [Abstract][Full Text] [Related]
3. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
4. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract.
Williams EA; Montesion M; Lincoln V; Tse JY; Hiemenz MC; Mata DA; Shah BB; Shoroye A; Alexander BM; Werth AJ; Foley-Peres K; Milante RR; Ross JS; Ramkissoon SH; Williams KJ; Adhikari LJ; Zuna RE; LeBoit PE; Lin DI; Elvin JA
Am J Surg Pathol; 2022 Jun; 46(6):729-741. PubMed ID: 35034043
[TBL] [Abstract][Full Text] [Related]
5. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
6. Targeted exome sequencing profiles genetic alterations in leiomyosarcoma.
Agaram NP; Zhang L; LeLoarer F; Silk T; Sung YS; Scott SN; Kuk D; Qin LX; Berger MF; Antonescu CR; Singer S
Genes Chromosomes Cancer; 2016 Feb; 55(2):124-30. PubMed ID: 26541895
[TBL] [Abstract][Full Text] [Related]
7. Integrated mutational landscape analysis of uterine leiomyosarcomas.
Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
[TBL] [Abstract][Full Text] [Related]
8. Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival.
Anderson ND; Babichev Y; Fuligni F; Comitani F; Layeghifard M; Venier RE; Dentro SC; Maheshwari A; Guram S; Wunker C; Thompson JD; Yuki KE; Hou H; Zatzman M; Light N; Bernardini MQ; Wunder JS; Andrulis IL; Ferguson P; Razak ARA; Swallow CJ; Dowling JJ; Al-Awar RS; Marcellus R; Rouzbahman M; Gerstung M; Durocher D; Alexandrov LB; Dickson BC; Gladdy RA; Shlien A
Nat Commun; 2021 Jul; 12(1):4496. PubMed ID: 34301934
[TBL] [Abstract][Full Text] [Related]
9. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.
Beck AH; Lee CH; Witten DM; Gleason BC; Edris B; Espinosa I; Zhu S; Li R; Montgomery KD; Marinelli RJ; Tibshirani R; Hastie T; Jablons DM; Rubin BP; Fletcher CD; West RB; van de Rijn M
Oncogene; 2010 Feb; 29(6):845-54. PubMed ID: 19901961
[TBL] [Abstract][Full Text] [Related]
10. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
[TBL] [Abstract][Full Text] [Related]
11. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.
Mäkinen N; Aavikko M; Heikkinen T; Taipale M; Taipale J; Koivisto-Korander R; Bützow R; Vahteristo P
PLoS Genet; 2016 Feb; 12(2):e1005850. PubMed ID: 26891131
[TBL] [Abstract][Full Text] [Related]
12. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline
Thibodeau ML; Reisle C; Zhao E; Martin LA; Alwelaie Y; Mungall KL; Ch'ng C; Thomas R; Ng T; Yip S; J Lim H; Sun S; Young SS; Karsan A; Zhao Y; Mungall AJ; Moore RA; J Renouf D; Gelmon K; Ma YP; Hayes M; Laskin J; Marra MA; Schrader KA; Jones SJM
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28514723
[TBL] [Abstract][Full Text] [Related]
14. Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.
Marino-Enriquez A; Novotny JP; Gulhan DC; Klooster I; Tran AV; Kasbo M; Lundberg MZ; Ou WB; Tao DL; Pilco-Janeta DF; Mao VY; Zenke FT; Leeper BA; Gokhale PC; Cowley GS; Baker LH; Ballman KV; Root DE; Albers J; Park PJ; George S; Fletcher JA
Clin Cancer Res; 2023 Dec; 29(24):5128-5139. PubMed ID: 37773632
[TBL] [Abstract][Full Text] [Related]
15. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
[TBL] [Abstract][Full Text] [Related]
16.
Williams EA; Sharaf R; Decker B; Werth AJ; Toma H; Montesion M; Sokol ES; Pavlick DC; Shah N; Williams KJ; Venstrom JM; Alexander BM; Ross JS; Albacker LA; Lin DI; Ramkissoon SH; Elvin JA
JCO Precis Oncol; 2020; 4():. PubMed ID: 33015533
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.
Lee PJ; Yoo NS; Hagemann IS; Pfeifer JD; Cottrell CE; Abel HJ; Duncavage EJ
Exp Mol Pathol; 2017 Feb; 102(1):156-161. PubMed ID: 28093192
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
Hemming ML; Bhola P; Loycano MA; Anderson JA; Taddei ML; Doyle LA; Lavrova E; Andersen JL; Klega KS; Benson MR; Crompton BD; Raut CP; George S; Letai A; Demetri GD; Sicinska E
Clin Cancer Res; 2022 Jun; 28(11):2397-2408. PubMed ID: 35325095
[TBL] [Abstract][Full Text] [Related]
19. Leiomyosarcomas: whole genome sequencing for a whole biology characterization.
Chibon F; Darbo E; Pérot G
Curr Opin Oncol; 2019 Jul; 31(4):317-321. PubMed ID: 31033567
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
